Showing 301-310 of 352 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| mIL-2/CD25 fusion protein and BTK inhibitor combination therapy for T1D | University of Miami | Wasif Khan | Cures | 01-May-2023 to 30-April-2027 | $974.996,00 |
| Dock2-mediated T cell migration as a targetable shared mechanism in autoimmunity | University of Pittsburgh | Alok Joglekar | Cures | 01-September-2025 to 28-February-2027 | $149.999,05 |
| Engineered Regulatory T cells for Suppression of Type 1 Diabetes | University of Pittsburgh | Alok Joglekar | Cures | 01-August-2026 to 31-July-2028 | $187.584,10 |
| New approach for tolerance induction after allogeneic islets transplantation | University of Pittsburgh | Eric Lagasse | Cures | 01-September-2026 to 31-August-2027 | $249.994,05 |
| Insulin dose and vascular complications in T1D: its role beyond insulin resistance and glycemia | University of Pittsburgh | Rachel Miller | Improving Lives | 01-July-2026 to 30-June-2029 | $749.947,12 |
| Can Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Mitigate Diabetic Ketoacidosis Risk? | University of Texas Health Science Center at San Antonio | Muhammad Abdul-Ghani | Improving Lives | 01-June-2019 to 31-December-2026 | $1.573.835,31 |
| Structural approaches to understand biased insulin signaling and design glucose-binding proteins for smart insulin therapeutics | University of Utah | Amber Vogel | Improving Lives | 01-March-2024 to 28-February-2027 | $228.995,00 |
| Optimization of fast-acting venom insulins as therapeutic candidates for T1D | University of Utah | Helena Safavi | Improving Lives | 01-September-2022 to 31-August-2026 | $890.372,53 |
| Randomized trial of semaglutide for diabetic kidney disease in type 1 diabetes | University of Washington | Ian De Boer | Improving Lives | 01-September-2023 to 31-March-2028 | $2.107.411,00 |
| Thermally responsive minimally invasive proangiogenic placeholder for cell transplantation for Type 1 Diabetes | University of Washington | Patrick Stayton | Cures | 01-November-2025 to 31-October-2028 | $894.965,96 |